Separately, Zacks Investment Research lowered OpGen from a buy rating to a hold rating in a research report on Wednesday, November 7th.
OPGN opened at $1.05 on Wednesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.43 and a current ratio of 1.56. OpGen has a 1 year low of $1.02 and a 1 year high of $7.60.
OpGen (NASDAQ:OPGN) last posted its quarterly earnings results on Tuesday, November 13th. The medical research company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. OpGen had a negative return on equity of 238.35% and a negative net margin of 395.63%. The business had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.56 million. On average, sell-side analysts expect that OpGen will post -2.19 earnings per share for the current year.
A hedge fund recently bought a new stake in OpGen stock. B. Riley Financial Inc. acquired a new position in OpGen Inc (NASDAQ:OPGN) during the second quarter, according to its most recent filing with the SEC. The firm acquired 138,000 shares of the medical research company’s stock, valued at approximately $246,000. B. Riley Financial Inc. owned about 2.22% of OpGen as of its most recent filing with the SEC. Institutional investors and hedge funds own 4.08% of the company’s stock.
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Featured Story: Do Tariffs Work?
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.